logo
logo

Actym Therapeutics Raises $34 Million Series A

Apr 27, 2020•about 5 years ago

Amount Raised

$34 Million

Round Type

series a

Berkeley

Description

Actym Therapeutics, a privately-held immuno-oncology company, announced today the completion of a $34 million series A financing led by Boehringer Ingelheim Venture Fund (BIVF) and Panacea Venture, with participation from Illumina Ventures, Korea Investment Partners (KIP), and JLo Ventures.  The company will use the proceeds to advance development of immunotherapies from its microbial-based STACT platform into the clinic for the treatment of various cancers.  Actym is led by industry veterans Christopher Thanos, Ph.D., Chief Executive Officer, Laura Hix Glickman, Ph.D., Vice President Research, and Mark Frohlich, M.D., Chief Medical Advisor.

Company Information

Company

Actym

Location

Berkeley, California, United States

About

Actym Therapeutics is based in Berkeley, California and was founded in 2017 by Christopher Thanos Ph.D., Laura Hix Glickman, Ph.D., and Amit Kumar, Ph.D.  The company has developed a microbial-based immunotherapy platform called STACT (S. Typhimurium Attenuated Cancer Therapy).  In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue.  Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells.   Many of these payloads are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after IV dosing.  Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech